Although they showed a strong potential as insulin sensitizers in T2DM patients, due to their high affinity for binding to PPARγ, they were withdrawn from market, because different adverse side effects in TZD-treated patients affected by T2DM have been evidenced. The gene discussed is PPARG; the disease is type 2 diabetes mellitus.